4QK Stock Chart & Stats
€1.31
<€0.01(0.46%)
At close: 4:00 PM EDT
€1.31
<€0.01(0.46%)
Day’s Range― - ―
52-Week Range€0.83 - €3.09
Previous CloseN/A
Volume0.00
Average Volume (3M)145.00
Market Cap
€130.58M
Enterprise Value€155.29
Total Cash (Recent Filing)€65.56M
Total Debt (Recent Filing)€72.90M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding107,563,230
10 Day Avg. Volume85
30 Day Avg. Volume145
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)2.02
P/FCF Ratio-5.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.37Price Target Upside386.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€63.69M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Revenue GrowthSustained high gross margins (~82%) and positive revenue growth signal durable unit economics for enzyme products and services. Strong margins provide structural capacity to fund R&D and scale manufacturing while absorbing SG&A, supporting long-term margin sustainability if commercial mix holds.
Profitable Small-molecule Biocatalysis BusinessA profitable, established small-molecule segment generates recurring product revenues and real-world validation through 13 branded products. This cash-positive franchise underpins platform investment, reduces reliance on single projects, and strengthens commercial credibility with pharma/CDMO partners.
Added Liquidity From Equity Offering And Stated Cash RunwayThe $23.1M net proceeds from the July 2026 equity offering, combined with management's stated runway to end-2027, meaningfully extend funding for the GMP build and scale-up. This reduces near-term financing pressure and gives time to convert partnerships and operational milestones.
Bears Say
Rising Leverage And Weaker Balance SheetMaterial increase in leverage erodes financial flexibility and elevates refinancing and interest risks. With equity diminished by ongoing losses, higher debt magnifies downside in execution setbacks and constrains strategic options for funding GMP build or absorbing delayed partner payments.
Persistent Negative Operating And Free Cash FlowOngoing cash burn requires recurring external funding or material margin/profit improvement to attain self-sufficiency. Continued negative operating and free cash flow can force dilutive financings, limit R&D/capex flexibility, and increase vulnerability if partner milestones slip.
Execution And Revenue Concentration RiskA quarter driven by one-time Merck recognition highlights concentration and timing risk. Back-half weighted guidance, ongoing scale-up (100g to 0.5kg) and uncertain partnership conversion mean durable revenue depends on executing technical scale, converting CDMO/pharma talks, and proving repeatable commercial demand.
Codexis News
4QK FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was €0.83 and its highest was €3.09 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is €130.58M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Aug 11, 2026 which is in 5 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on May 07, 2026. The company reported -€0.087 earnings per share for the quarter, beating the consensus estimate of -€0.119 by €0.032.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.12.
How many shares outstanding does Codexis have?
Codexis has 107,563,230 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -€0.087 in its last earnings report, beating expectations of -€0.119. Following the earnings report the stock price went up 8.966%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in DE:4QK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Codexis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.37 (386.23% Upside)
€6.37 (386.23% Upside)
Insider Transactions
Sold Shares
Worth €5.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.37%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
4QK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong top-line acceleration (Q1 revenue +≈103%), materially improved product margins (71% vs 55%), a substantially reduced net loss, promising platform innovations (stereochemical control) and a healthy sales funnel with CDMO interest. Offsetting these positives are reliance on a large one-time Merck revenue recognition for the quarter, a declining cash balance, remaining technical and scale-up risks (100 g to 0.5 kg target), and pending clinical/efficacy data to validate stereochemistry benefits. Management reiterated full-year guidance and expects the business to be operationally ready with a new GMP facility by end of 2027, but execution and partnership conversion timing will be critical.View all DE:4QK earnings summaries4QK Stock 12 Month Forecast
Average Price Target
€6.37
▲(386.23% Upside)
Technical Analysis
Cartesian Therapeutics
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
OmniAb
―